Skip to main content

Advertisement

SpringerLink
Log in

A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies

  • Health Economics (N Khera, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Patients treated for a hematologic malignancy are at risk for treatment-related complications. As the goal of therapy is frequently curative, treatments are especially intensive and long-term toxicity is common. Chemotherapy and radiation are associated with increased risk for cardiac and pulmonary disease, endocrine disorders, infertility, sexual dysfunction, second cancers, and psychosocial distress. The risk for each complication is dictated by patient characteristics including age, co-morbidities, and genetic predispositions, as well as the specifics of therapy. Survivors of pediatric cancers and allogeneic hematopoietic stem cell transplantation have unique risks due to vulnerable age at time of toxic exposure and ongoing immune dysfunction, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Reulen RC et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172–9.

    Article  CAS  PubMed  Google Scholar 

  2. Tukenova M et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308–15.

    Article  PubMed  Google Scholar 

  3. Hudson MM et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lipshultz SE et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association. Circulation. 2013;128(17):1927–95.

    Article  PubMed  Google Scholar 

  5. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol. 2012;30(30):3657–64. This article represents a comprehensive review of the late cardiac toxicities occurring after cancer treatment.

  6. Armstrong GT et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–80. This article describes the impact of traditional modifiable cardiovascular risk factors on risk for major cardiac events among adult survivors of childhood cancer.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Steinherz LJ et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics. 1992;89(5 Pt 1):942–9.

    CAS  PubMed  Google Scholar 

  8. Sieswerda E et al. The Dutch childhood oncology group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol. 2012;23(8):2191–8.

    Article  CAS  PubMed  Google Scholar 

  9. Chow EJ et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2015;33(5):394–402. This article describes the creation and validation of a prediction model for heart failure among childhood cancer survivors.

    Article  PubMed  Google Scholar 

  10. Blanco JG et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the children’s oncology group. J Clin Oncol. 2012;30(13):1415–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Visscher H et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422–8.

    Article  PubMed  Google Scholar 

  12. Lipshultz SE et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013;119(19):3555–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Visscher H et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60(8):1375–81.

    Article  CAS  PubMed  Google Scholar 

  14. Wang X et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol. 2014;32(7):647–53.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53(2):121–9.

    Article  CAS  PubMed  Google Scholar 

  16. D’Alessandra Y et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31(22):2765–73.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Horie T et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010;87(4):656–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Walker J et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28(21):3429–36.

    Article  PubMed  Google Scholar 

  19. Fallah-Rad N et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57(22):2263–70.

    Article  CAS  PubMed  Google Scholar 

  20. Sawaya H et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Lipshultz SE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Blaes AH et al. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat. 2010;122(2):585–90.

    Article  CAS  PubMed  Google Scholar 

  23. Cardinale D et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–81.

    Article  CAS  PubMed  Google Scholar 

  24. Nakamae H et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492–8.

    Article  CAS  PubMed  Google Scholar 

  25. Bosch X et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62. A prospective randomized trial demonstrating cardioprotection in patients receiving ACE-I and beta-blockers with chemotherapy.

    Article  CAS  PubMed  Google Scholar 

  26. Bowers DC et al. Stroke as a late treatment effect of Hodgkin’s disease: a report from the childhood cancer survivor study. J Clin Oncol. 2005;23(27):6508–15.

    Article  PubMed  Google Scholar 

  27. De Bruin ML et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928–37.

    Article  PubMed  Google Scholar 

  28. Schellong G et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55(6):1145–52.

    Article  PubMed  Google Scholar 

  29. Heidenreich PA et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25(1):43–9.

    Article  PubMed  Google Scholar 

  30. Chen AB et al. Cost effectiveness and screening interval of lipid screening in Hodgkin’s lymphoma survivors. J Clin Oncol. 2009;27(32):5383–9.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Hoppe RT et al. Hodgkin lymphoma. J Natl Compr Cancer Netw. 2011;9(9):1020–58.

    CAS  Google Scholar 

  32. Martin WG et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23(30):7614–20.

    Article  CAS  PubMed  Google Scholar 

  33. Gilson AJ, Sahn SA. Reactivation of bleomycin lung toxicity following oxygen administration. A second response to corticosteroids. Chest. 1985;88(2):304–6.

    Article  CAS  PubMed  Google Scholar 

  34. Ingrassia 3rd TS et al. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc. 1991;66(2):173–8.

    Article  PubMed  Google Scholar 

  35. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol. 1998;160(4):1347–52.

    Article  CAS  PubMed  Google Scholar 

  36. Aakre BM et al. Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc. 2014;89(2):181–9. This article demonstrates that the risk of post-operative ARDS in bleomycin-exposed patients is low, and may be related to smoking.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Amraoui K et al. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients. Eur Respir Rev. 2013;22(127):93–5.

    Article  PubMed  Google Scholar 

  38. Miyakoshi S et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492–4.

    Article  CAS  PubMed  Google Scholar 

  39. Zappasodi P et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 2007;25(22):3380–1.

    Article  PubMed  Google Scholar 

  40. Ohnishi K et al. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20(6):1162–4.

    Article  CAS  PubMed  Google Scholar 

  41. Bergeron A et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176(8):814–8.

    Article  CAS  PubMed  Google Scholar 

  42. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med. 1991;325(9):599–605.

    Article  CAS  PubMed  Google Scholar 

  43. Jereczek-Fossa BA et al. Radiotherapy-induced thyroid disorders. Cancer Treat Rev. 2004;30(4):369–84.

    Article  CAS  PubMed  Google Scholar 

  44. Ha CS et al. ACR appropriateness criteria follow-up of Hodgkin lymphoma. J Am Coll Radiol. 2014;11(11):1026–1033.e3.

    Article  PubMed  Google Scholar 

  45. Sanders JE et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood. 2009;113(2):306–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Majhail NS et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348–71. This article represents a comprehensive review of short-term and long-term primary-care-based recommendations for recipients of hematopoietic cell transplantation.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18(1):117–21.

    Article  CAS  PubMed  Google Scholar 

  48. Wallace WH et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62(3):738–44.

    Article  PubMed  Google Scholar 

  49. Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril. 2013;100(5):1180–6.

    Article  CAS  PubMed  Google Scholar 

  50. Howell SJ et al. Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. Br J Cancer. 2000;82(4):789–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Greenfield DM et al. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab. 2007;92(9):3476–82.

    Article  CAS  PubMed  Google Scholar 

  52. Wood ME et al. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734–45. This article is a comprehensive overview of second cancers in adult-onset cancer survivors.

    Article  PubMed  Google Scholar 

  53. Travis LB et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301.

    Article  CAS  PubMed  Google Scholar 

  54. Ng AK et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101–8.

    Article  PubMed  Google Scholar 

  55. Aleman BM et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431–9.

    Article  PubMed  Google Scholar 

  56. van Leeuwen FE et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487–97.

    PubMed  Google Scholar 

  57. Wong TN et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552–5. This article describes novel insights on the mechanism by which cytotoxic chemotherapy drives leukemogenesis (development of therapy-related acute myeloid leukemia and myelodysplastic syndrome).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Majhail NS. Old and new cancers after hematopoietic-cell transplantation. Hematol Am Soc Hematol Educ Program. 2008;142–9.

  59. Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21(6):476–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Luskin MR et al. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen. Clin Lymphoma Myeloma Leuk. 2014;14(2):e55–8.

    Article  PubMed  Google Scholar 

  61. Swerdlow AJ et al. Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British national lymphoma investigation. BMJ. 1992;304(6835):1137–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Daniels LA et al. Long-term risk of secondary skin cancers after radiation therapy for Hodgkin’s lymphoma. Radiother Oncol. 2013;109(1):140–5.

    Article  PubMed  Google Scholar 

  63. Ng AK. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects. Blood. 2014;124(23):3373–9. This article summarizes recent recommendations for long-term care of survivors of Hodgkin lymphoma.

    Article  CAS  PubMed  Google Scholar 

  64. Travis LB et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97(19):1428–37.

    Article  PubMed  Google Scholar 

  65. Inskip PD et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27(24):3901–7.

    Article  PubMed Central  PubMed  Google Scholar 

  66. De Bruin ML et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–46.

    Article  PubMed  Google Scholar 

  67. Omer B et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol. 2012;158(5):615–25.

    Article  PubMed  Google Scholar 

  68. Moskowitz CS et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217–23. This study defined risk factors for breast cancer among women treated for childhood cancer with chest radiation.

    Article  PubMed Central  PubMed  Google Scholar 

  69. Ng AK et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013;31(18):2282–8. This study established prospectively the increased sensitivity of combined mammogram plus MRI screening for breast cancer in Hodgkin lymphoma survivors.

    Article  PubMed  Google Scholar 

  70. Milano MT et al. Long-term survival among patients with Hodgkin’s lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28(34):5088–96.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Schoenfeld JD et al. Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Ann Oncol. 2012;23(7):1813–8.

    Article  CAS  PubMed  Google Scholar 

  72. Wattson DA et al. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2014;90(2):344–53.

    Article  PubMed  Google Scholar 

  73. Behringer K et al. Sexual quality of life in Hodgkin lymphoma: a longitudinal analysis by the German Hodgkin study group. Br J Cancer. 2013;108(1):49–57.

    PubMed Central  CAS  PubMed  Google Scholar 

  74. Greaves P et al. Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol. 2014;164(4):526–35.

    Article  PubMed  Google Scholar 

  75. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril. 2013;100(4):916–21. This article represents a comprehensive review of the different causes and treatment modalities for sexual dysfunction for women occuring after cancer treatment.

    Article  PubMed  Google Scholar 

  76. Goldfarb S et al. Sexual and reproductive health in cancer survivors. Semin Oncol. 2013;40(6):726–44.

    Article  PubMed  Google Scholar 

  77. Ford JS et al. Psychosexual functioning among adult female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2014;32(28):3126–36.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Foster RH, Stern M. Peer and romantic relationships among adolescent and young adult survivors of childhood hematological cancer: a review of challenges and positive outcomes. Acta Haematol. 2014;132(3):375–82.

    Article  PubMed  Google Scholar 

  79. Kamen C, et al. Disparities in psychological distress impacting lesbian, gay, bisexual and transgender cancer survivors. Psychooncology. 2015. doi:10.1002/pon.3746

  80. Jadoul P, Kim SS, Committee IP. Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet. 2012;29(6):479–87.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Loren AW et al. Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10. This article represents a comprehensive review of expert consensus guidelines regarding infertility risks and fertility preservation options for men and women diagnosed with cancer.

    Article  PubMed  Google Scholar 

  82. De Vos M, Smitz J, Woodruff TK. Fertility preservation in women with cancer. Lancet. 2014;384(9950):1302–10.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Tournaye H, Dohle GR, Barratt CLR. Fertility preservation in men with cancer. Lancet. 2014;384(9950):1295–301. This article represents a comprehensive review of treatment modalities for men diagnosed with cancer.

    Article  PubMed  Google Scholar 

  84. Letourneau JM et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Scanlon M et al. Patient satisfaction with physician discussions of treatment impact on fertility, menopause and sexual health among pre-menopausal women with cancer. J Cancer. 2012;3:217–25.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Shapira M et al. Fertility preservation in young females with hematological malignancies. Acta Haematol. 2014;132(3–4):400–13.

    Article  PubMed  Google Scholar 

  87. Assouline E et al. Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women’s fertility. Clin Lymphoma Myeloma Leuk. 2013;13(6):704–10.

    Article  PubMed  Google Scholar 

  88. Di Paola R et al. Anti-Mullerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies. Oncologist. 2013;18(12):1307–14.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  89. Blumenfeld Z, Katz G, Evron A. ‘An ounce of prevention is worth a pound of cure’: the case for and against GnRH-agonist for fertility preservation. Ann Oncol. 2014;25(9):1719–28.

    Article  CAS  PubMed  Google Scholar 

  90. Loge JH et al. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol. 1999;17(1):253–61.

    CAS  PubMed  Google Scholar 

  91. Heutte N et al. Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10(12):1160–70.

    Article  PubMed  Google Scholar 

  92. Hjermstad MJ et al. Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer. 2006;42(3):327–33.

    Article  PubMed  Google Scholar 

  93. Ovayolu O et al. Symptoms and quality of life: before and after stem cell transplantation in cancer. Pak J Med Sci. 2013;29(3):803–8.

    Article  PubMed Central  PubMed  Google Scholar 

  94. Syrjala KL et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA. 2004;291(19):2335–43.

    Article  CAS  PubMed  Google Scholar 

  95. El-Jawahri AR et al. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer. 2015;121(6):951–9. This represents a prosepctive study of quality of life patients and family caregivers undergoing HSCT; baseline depression and anxiety predicted worse QOL throughout hospitalization.

    Article  PubMed  Google Scholar 

  96. Mosher CE et al. Quality of life concerns and depression among hematopoietic stem cell transplant survivors. Support Care Cancer. 2011;19(9):1357–65.

    Article  PubMed Central  PubMed  Google Scholar 

  97. Gupta V et al. A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning. Biol Blood Marrow Transplant. 2012;18(1):113–24.

    Article  PubMed  Google Scholar 

  98. Norkin M, Hsu JW, Wingard JR. Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. Semin Hematol. 2012;49(1):104–9.

    Article  PubMed  Google Scholar 

  99. Lee SJ et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38(4):305–10.

    Article  CAS  PubMed  Google Scholar 

  100. Pallua S et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant. 2010;45(10):1534–9.

    Article  CAS  PubMed  Google Scholar 

  101. Sun CL et al. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the bone marrow transplant survivor study (BMTSS). Blood. 2011;118(17):4723–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Kopp M et al. Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls. Eur J Haematol. 2005;74(4):304–8.

    Article  PubMed  Google Scholar 

  103. Jim HS et al. Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer. 2012;118(13):3407–16.

    Article  PubMed Central  PubMed  Google Scholar 

  104. Kirchhoff AC, Leisenring W, Syrjala KL. Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation. J Cancer Surviv. 2010;4(1):33–44.

    Article  PubMed Central  PubMed  Google Scholar 

  105. Krull KR et al. Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. J Clin Oncol. 2012;30(29):3618–24.

    Article  PubMed Central  PubMed  Google Scholar 

  106. Goldsby RE et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. J Clin Oncol. 2010;28(2):324–31.

    Article  PubMed Central  PubMed  Google Scholar 

  107. Correa DD et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62(4):548–55.

    Article  CAS  PubMed  Google Scholar 

  108. Correa DD et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91(3):315–21.

    Article  CAS  PubMed  Google Scholar 

  109. Syrjala KL et al. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood. 2004;104(10):3386–92.

    Article  CAS  PubMed  Google Scholar 

  110. Basinski JR et al. Impact of delirium on distress, health-related quality of life, and cognition 6 months and 1 year after hematopoietic cell transplant. Biol Blood Marrow Transplant. 2010;16(6):824–31.

    Article  PubMed Central  PubMed  Google Scholar 

  111. Harder H et al. Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer. 2002;95(1):183–92.

    Article  PubMed  Google Scholar 

  112. Syrjala KL et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011;29(17):2397–404.

    Article  PubMed Central  PubMed  Google Scholar 

  113. Smith SK et al. Post-traumatic stress outcomes in non-Hodgkin’s lymphoma survivors. J Clin Oncol. 2008;26(6):934–41.

    Article  PubMed Central  PubMed  Google Scholar 

  114. Mosher CE et al. Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology. 2009;18(2):113–27.

    Article  PubMed Central  PubMed  Google Scholar 

  115. Loberiza Jr FR et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002;20(8):2118–26.

    Article  PubMed  Google Scholar 

  116. Tichelli A et al. Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the late effects working party of the European group for blood and marrow transplantation (EBMT). Cancer. 2013;119(11):2012–21.

    Article  PubMed Central  PubMed  Google Scholar 

  117. DuHamel KN et al. Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation. J Clin Oncol. 2010;28(23):3754–61.

    Article  PubMed Central  PubMed  Google Scholar 

  118. Arora NK et al. Patient-physician communication about health-related quality-of-life problems: are non-Hodgkin lymphoma survivors willing to talk? J Clin Oncol. 2013;31(31):3964–70.

    Article  PubMed Central  PubMed  Google Scholar 

  119. Hashmi S et al. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant. 2015;21(2):225–32. This article represents a comprehensive review of best-practice guidelines for recipients of hematopoietic cell transplantation, focusing on dedicated long-term follow-up clinics.

    Article  PubMed  Google Scholar 

  120. Jesudas R et al. Reviewing the follow-up care of pediatric patients’ status post-hematopoietic stem cell transplantation for the primary care pediatrician. Clin Pediatr (Phila). 2013;52(6):487–95.

    Article  Google Scholar 

  121. Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(30):3746–51.

    Article  PubMed Central  PubMed  Google Scholar 

  122. Majhail NS et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117(1):316–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  123. Marini BL, et al. Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients. Biol Blood Marrow Transplant. 2014.

  124. Hamilton JG et al. Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoietic stem cell transplantation. Psychooncology. 2013;22(4):911–21.

    Article  PubMed Central  PubMed  Google Scholar 

  125. Wulff-Burchfield EM, Jagasia M, Savani BN. Long-term follow-up of informal caregivers after allo-SCT: a systematic review. Bone Marrow Transplant. 2013;48(4):469–73.

    Article  CAS  PubMed  Google Scholar 

  126. Virtue SM et al. Psychological distress and psychiatric diagnoses among primary caregivers of children undergoing hematopoietic stem cell transplant: an examination of prevalence, correlates, and racial/ethnic differences. Gen Hosp Psychiatry. 2014;36(6):620–6.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Beattie S, Lebel S, Tay J. The influence of social support on hematopoietic stem cell transplantation survival: a systematic review of literature. PLoS One. 2013;8(4):e61586.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  128. Bevans M et al. A problem-solving education intervention in caregivers and patients during allogeneic hematopoietic stem cell transplantation. J Health Psychol. 2014;19(5):602–17.

    Article  PubMed Central  PubMed  Google Scholar 

  129. Landier W et al. Development of risk-based guidelines for pediatric cancer survivors: the children’s oncology group long-term follow-up guidelines from the children’s oncology group late effects committee and nursing discipline. J Clin Oncol. 2004;22(24):4979–90.

    Article  PubMed  Google Scholar 

  130. Casillas J. et al., Identifying predictors of longitudinal decline in the level of medical care received by adult survivors of childhood cancer: a report from the childhood cancer survivor study. Health Serv Res. 2015. doi:10.1111/1475-6773.12282

  131. Suh E et al. General internists’ preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med. 2014;160(1):11–7.

    Article  PubMed Central  PubMed  Google Scholar 

  132. McCabe MS et al. American society of clinical oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31(5):631–40.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Marlise R. Luskin, Rahul Banerjee, Sarah Del Percio, and Alison W. Loren each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Hematology—Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Marlise R. Luskin, Sarah Del Percio & Alison W. Loren

  2. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Rahul Banerjee

Authors
  1. Marlise R. Luskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahul Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Del Percio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alison W. Loren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alison W. Loren.

Additional information

This article is part of the Topical Collection on Health Economics

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luskin, M.R., Banerjee, R., Del Percio, S. et al. A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. Curr Hematol Malig Rep 10, 225–236 (2015). https://doi.org/10.1007/s11899-015-0274-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-015-0274-1

Keywords

Search

Navigation